WASHINGTON — The Trump administration is ready to defend its sweeping new drug pricing proposals. In a new Q&A, obtained by STAT, its authors parry several key criticisms — some already aired, some expected — from drug makers and other groups.
The document, which is expected to be published later Tuesday according to a senior administration official, represents a quick response from the administration, which only unveiled the policy in an address on Thursday.
About the Author Reprints
